Abstract
Isolated extramedullary (EM) relapses of acute myelogenous leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) have been reported to be rare, and are usually followed by bone marrow relapses. We report a 49-year-old man with AML with the unfavorable chromosome abnormality 7q-, who was treated by allo-HSCT. Fifteen months after allo-HSCT, the patient initially developed a relapse only in his inguinal lymph nodes, and then bone marrow relapse became evident one month after the EM relapse. Subsequently, the patient received chemotherapy and a second allo-HSCT from another donor, but he suffered another relapse in different EM sites including the skin and central nervous system with a persistently normal marrow. This case is characterized by repeated relapses in isolated EM sites after allo-HSCT and suggests that the anti-leukemic effects of chemotherapy and/or graft-versus-leukemia effects in the EM sites might not be so uniformly effective as that in the marrow. Accordingly, we should be aware that AML relapses can occur repeatedly only in isolated EM sites post allo-HSCT, resulting in treatment failure and a poor prognosis.
| Original language | English |
|---|---|
| Pages (from-to) | 1011-1014 |
| Number of pages | 4 |
| Journal | Internal Medicine |
| Volume | 46 |
| Issue number | 13 |
| DOIs | |
| Publication status | Published - Jul 2 2007 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Internal Medicine
Cite this
Repeated relapses of acute myelogenous leukemia in the isolated extramedullary sites following allogeneic bone marrow transplantations. / Kikushige, Yoshikane; Takase, Ken; Sata, Keiko; Aoki, Ken Ichi; Numata, Akihiko; Miyamoto, Toshihiro; Fukuda, Takahiro; Gondo, Hisashi; Harada, Mine; Nagafuji, Koji.
In: Internal Medicine, Vol. 46, No. 13, 02.07.2007, p. 1011-1014.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Repeated relapses of acute myelogenous leukemia in the isolated extramedullary sites following allogeneic bone marrow transplantations
AU - Kikushige, Yoshikane
AU - Takase, Ken
AU - Sata, Keiko
AU - Aoki, Ken Ichi
AU - Numata, Akihiko
AU - Miyamoto, Toshihiro
AU - Fukuda, Takahiro
AU - Gondo, Hisashi
AU - Harada, Mine
AU - Nagafuji, Koji
PY - 2007/7/2
Y1 - 2007/7/2
N2 - Isolated extramedullary (EM) relapses of acute myelogenous leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) have been reported to be rare, and are usually followed by bone marrow relapses. We report a 49-year-old man with AML with the unfavorable chromosome abnormality 7q-, who was treated by allo-HSCT. Fifteen months after allo-HSCT, the patient initially developed a relapse only in his inguinal lymph nodes, and then bone marrow relapse became evident one month after the EM relapse. Subsequently, the patient received chemotherapy and a second allo-HSCT from another donor, but he suffered another relapse in different EM sites including the skin and central nervous system with a persistently normal marrow. This case is characterized by repeated relapses in isolated EM sites after allo-HSCT and suggests that the anti-leukemic effects of chemotherapy and/or graft-versus-leukemia effects in the EM sites might not be so uniformly effective as that in the marrow. Accordingly, we should be aware that AML relapses can occur repeatedly only in isolated EM sites post allo-HSCT, resulting in treatment failure and a poor prognosis.
AB - Isolated extramedullary (EM) relapses of acute myelogenous leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) have been reported to be rare, and are usually followed by bone marrow relapses. We report a 49-year-old man with AML with the unfavorable chromosome abnormality 7q-, who was treated by allo-HSCT. Fifteen months after allo-HSCT, the patient initially developed a relapse only in his inguinal lymph nodes, and then bone marrow relapse became evident one month after the EM relapse. Subsequently, the patient received chemotherapy and a second allo-HSCT from another donor, but he suffered another relapse in different EM sites including the skin and central nervous system with a persistently normal marrow. This case is characterized by repeated relapses in isolated EM sites after allo-HSCT and suggests that the anti-leukemic effects of chemotherapy and/or graft-versus-leukemia effects in the EM sites might not be so uniformly effective as that in the marrow. Accordingly, we should be aware that AML relapses can occur repeatedly only in isolated EM sites post allo-HSCT, resulting in treatment failure and a poor prognosis.
UR - http://www.scopus.com/inward/record.url?scp=34547890658&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34547890658&partnerID=8YFLogxK
U2 - 10.2169/internalmedicine.46.6384
DO - 10.2169/internalmedicine.46.6384
M3 - Article
C2 - 17603242
AN - SCOPUS:34547890658
VL - 46
SP - 1011
EP - 1014
JO - Internal Medicine
JF - Internal Medicine
SN - 0918-2918
IS - 13
ER -